Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 9/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11391846 | 0.90 | LIPE (0.67) | LIPELMNAMAPTNPSR1THRB | |
| SCHEMBL20466546 | 0.85 | RAB9A (0.69) | LIPELMNAMAPTNPSR1RAB9A | |
| SCHEMBL11351938 | 0.84 | MAPT (0.69) | LIPELMNAMAPTNPSR1THRB | |
| SCHEMBL8463930 | 0.84 | KDM4E (0.51) | LIPELMNAMAPTNPSR1THRB | |
| SCHEMBL8737052 | 0.84 | KDM4E (0.66) | LIPEMAPTNPSR1RAB9AKDM4E | |
| SCHEMBL16838765 | 0.83 | LMNA (0.59) | LIPELMNAMAPTNPSR1THRB | |
| SCHEMBL24690163 | 0.83 | NOS1 (0.43) | LIPELMNAMAPTTHRBMAPK1 | |
| SCHEMBL778928 | 0.81 | MEN1 (0.64) | RAB9AKDM4EPOLBMEN1KMT2A | |
| SCHEMBL6305053 | 0.80 | KDM4E (0.71) | LIPELMNAMAPTNPSR1THRB | |
| SCHEMBL21652204 | 0.80 | RAB9A (0.67) | LIPELMNAMAPTNPSR1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120129893-A1 | Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas | DUMAS JACQUES (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120129893-A1 | Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas | DUMAS JACQUES (US) | 2012-05-24 | — | — | US | disclosed |
| US-20070244120-A1 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER HEALTHCARE LLC | 2007-10-18 | — | — | US | disclosed |
| US-20070244120-A1 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | BAYER HEALTHCARE LLC | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244120-A1 | INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS | BRAF, RAF1, ARAF | LIPE 3630/4885LMNA 3637/4885MAPT 3056/4885 |
| US-20120129893-A1 | Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas | BRAF, RAF1, ARAF | LIPE 3630/4885LMNA 3637/4885MAPT 3056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.